点击上方汇丰晋信基金订阅随着创新药行业产业链的持续优化和政策支持力度的不断加大,中国创新药产业或正迎来复苏的新起点。而刚刚发布的上市公司三季报,无疑成为了观察创新药行业动态和未来发展前景的重要窗口。本周价值君特邀汇丰晋信医疗先锋基金 基金经理 李博康,从三季报角度为大家详细分析创新药板块的未来机会。李博康汇丰晋信医疗先锋基金基金经理Q1经历前期的强势表现以后,10月以来创新药板块波动加大,您觉得...
Source Link点击上方汇丰晋信基金订阅随着创新药行业产业链的持续优化和政策支持力度的不断加大,中国创新药产业或正迎来复苏的新起点。而刚刚发布的上市公司三季报,无疑成为了观察创新药行业动态和未来发展前景的重要窗口。本周价值君特邀汇丰晋信医疗先锋基金 基金经理 李博康,从三季报角度为大家详细分析创新药板块的未来机会。李博康汇丰晋信医疗先锋基金基金经理Q1经历前期的强势表现以后,10月以来创新药板块波动加大,您觉得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.